Tarrytown-based Regeneron Pharmaceuticals Inc. will webcast its presentation for the Goldman Sachs 31st Annual Global Healthcare Conference June 16. The presentation is scheduled for 5:40 p.m.
The session is accessible through www.regeneron.com on the “investor relations” page. An archived version of the presentation will be available after the live webcast through July 16.
The conference is to be held at the Century Plaza Hyatt Regency in Los Angeles.
Regeneron is expected to apprise investors and potential investors about Arcalyst (rilonacept) “injection for subcutaneous use,” its first commercialized product. The company also will address its therapeutic candidates in phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers, it reported.
Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer, according to Regeneron.
